semaglutide heart disease GLP-1 agonists like Ozempic may reduce cardiovascular events by 20% Oral semaglutide found to lower

Geerling BJ, Badart-Smook A, Stockbrgger RW, Brummer RJ

This high percentage means the medication effectively preserves vital functional skeletal muscle mass when patients consume adequate protein and engage in resistance training

A study comparing individuals who have similar weight loss, with and without the medication may elucidate if the risk reduction is from weight loss or the medication. Semaglutide is part of a class of drugs called glucagon-like peptide 1 (GLP-1) agonists, which help control glucose levels by increasing the release of insulin into the bloodstream

CD34 expression has also been described in a cellular blue nevus